Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01970579
Other study ID # AAG-G-H-1214
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date October 2013
Est. completion date December 2019

Study information

Verified date March 2020
Source B. Braun Melsungen AG
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the study is to assess the safety and efficacy of the paclitaxelreleasing balloon catheter SeQuent® Please P to treat de novo and restenotic lesions in the superficial femoral artery and the proximal two segments of the popliteal artery with reference diameters ≥ 4mm & ≤ 7mm and lesion lengths ≥ 4 cm & ≤ 27 cm. It is the intention of this trial to treat suitable target lesions with DCB only.


Recruitment information / eligibility

Status Completed
Enrollment 153
Est. completion date December 2019
Est. primary completion date December 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Willingness to treat the target lesion according to the DCB only concept

- Patients in Rutherford classes 2 through 4 (corresponding to Fontaine stage IIb to III)

- Patients eligible for peripheral revascularization by means of PTA

- Patients must be = 18 years of age

- Patients who are mentally and linguistically able to understand the aim of the study and to show sufficient compliance in following the study protocol

- Patients must agree to undergo the 6-month angiographic and clinical follow-up

- Patients must agree to undergo the 1 and 2 year clinical follow-up

- Patient is able to verbally acknowledge an understanding of the associated risks, benefits, and treatment alternatives to therapeutic options of this trial. The patients, by providing their informed consent, agree to these risks and benefits as stated in the patient informed consent document.

- Peripheral lesions in the native SFA or popliteal artery with reference vessel diameters between = 4.0 and = 7.0 mm, lesions lengths = 4 cm and = 27 cm as angiographically documented

- Diameter stenosis pre-procedure must be = 70%

- Target lesion in the SFA or popliteal artery (first two proximal segments)*.

* as far as applicable distance of the target lesion to a previously implanted stent should be about 1cm

- Vessels must have adequate runoff with at least one vessel to the foot.

- Treatment of max. two lesions is permitted.

Exclusion Criteria:

- Patients with Rutherford class 5 or 6

- Women who are known or suspected to be pregnant. Hence, patients will be advised to use an adequate birth control method up to and including the 6-month follow-up.

- Patients with an expected life span of less than 24 months

- Patients with bleeding diathesis in whom anticoagulation or anti-platelet medication is contraindicated

- Patients who had a cerebral stroke < 6 months prior to the procedure

- Patients with unstable angina pectoris

- Patients with acute myocardial infarction within the past 2 weeks

- Patient participates in other clinical trials involving any investigational device or drug that interfere with the effects to be studied in this trial.

- Interventional treatment at the contralateral leg within 2 weeks prior to or after the study intervention

- Untreated hyperthyroidism

- Patient has presence or history of severe renal failure (GFR < 30ml/min) and is therefore not eligible for angiography.

- Post transplantation of any organ or immune suppressive medication

- Other disease to jeopardize follow-up (e.g. malignoma)

- Addiction to any drug or to alcohol (WHO definition)

- Patients with clinically significant aneurysmal disease of the popliteal, femoral or iliac artery and patients with history of clinically significant abdominal aortic aneurysm

- Patients with any type of surgical/interventional procedures within 4 weeks prior to or planned after study intervention (if those may interfere with the peripheral study intervention and/or patient's ability to perform the follow up examinations)

- Conditions which prevent the intake of the double anti-platelet therapy for two months

- Patients with contraindication for drug-eluting balloon angioplasty given in the instruction for use

- Patients under administrative or judicial custody (§20 Act on Medical Devices, Germany)

- Strongly calcified lesions with circumferential presence of calcifications and a lesion length of > 4 cm

- Chronic total occlusions longer than 10 cm

- Lesion below the knee requiring treatment

- Target lesion within a bypass graft

- In-stent restenosis

- Lesions treated with DCB

- Concomitant use of atherectomy, cryoplasty or laser therapy

- Inflow lesion (proximal to the study lesion) with flow limitation not being successfully treated prior to the study lesion

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Paclitaxel coated balloon
Treatment of target lesion with study balloon (coated). Diameter of treatment balloon = RVD Each study balloon must only be used once (except postdilatation is necessary which may be done with the same balloon used for the initial dilatation) Treatment balloon must be 20 mm longer than lesion length (to assure balloon overlap of 10 mm proximal and distal to lesion) If two treatment balloons are necessary overlap between the balloon must be 10 mm Inflation pressure 7-10 atm Intraluminal defects or haziness should be treated with additional inflations and/or aggressive anti-platelet agents or bailout stenting
uncoated PTA catheter
Treatment of target lesion with study balloon (uncoated). Diameter of treatment balloon = RVD Each study balloon must only be used once (except postdilatation is necessary which may be done with the same balloon used for the initial dilatation) Treatment balloon must be 20 mm longer than lesion length (to assure balloon overlap of 10 mm proximal and distal to lesion) If two treatment balloons are necessary overlap between the balloon must be 10 mm Inflation pressure 7-10 atm Intraluminal defects or haziness should be treated with additional inflations and/or aggressive anti-platelet agents or bailout stenting.

Locations

Country Name City State
Germany Universitäts-Herzzentrum Freiburg Bad Krozingen Bad Krozingen
Germany Ev. Krankenhaus Hubertus Berlin
Germany Vivantes Klinikum Neukölln Berlin
Germany Klinikum der Otto-von-Guericke-Universität Magdeburg Magdeburg
Germany Klinikum Magdeburg Magdeburg
Germany Deutsches Herzzentrum München München
Germany RoMed Klinikum Rosenheim Rosenheim

Sponsors (1)

Lead Sponsor Collaborator
B. Braun Melsungen AG

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Late Lumen Loss 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT04848376 - Post-Market Clinical Follow-up Study of A-SPINE's Products
Recruiting NCT04584632 - The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery N/A
Completed NCT02834806 - BIONICS Israel Trial N/A
Recruiting NCT02395354 - Comparative Prospective Multicenter Randomized Study of Endoscopic Treatment of Stenosis in Crohn´s Disease N/A
Completed NCT00555659 - Prospective Clinical Evaluation of the New Aegis Plate for Anterior Interbody Fusions N/A
Withdrawn NCT00543348 - RCT of the Cutting Balloon Versus a High Pressure Balloon for the Treatment of Arteriovenous Fistula Stenoses N/A
Completed NCT00205101 - Clinical Outcome Study of the Triad Allograft for Posterior Lumbar Fusion
Terminated NCT04370041 - Dokimos Plus Aortic Valve Implant in 80 Patients Diagnosed With a Heart Valve Disease and Requiring Valve Replacement N/A
Recruiting NCT05053932 - Long-term Comparative Cerebrovascular Outcome After Transplantation vs Standard Care in Sickle Cell Anemia
Completed NCT02373852 - PMS Retrospective Study of WIRION Performance in Patients Undergoing Saphenous Vein Graft (SVG) Intervention
Completed NCT01873586 - OsteoStrux™ Collagen Ceramic Scaffold in Instrumented Lumbar Spine Fusion N/A
Completed NCT00540813 - Paclitaxel-Eluting Balloon Angioplasty and Coroflex™-Stents in the Treatment of Bifurcated Coronary Lesions N/A
Recruiting NCT00496639 - Stent vs. Angioplasty for Treatment of Thrombosed AV Grafts: Long-Term Outcomes N/A
Terminated NCT00254852 - Evaluation of Radiographic and Patient Outcomes Following Lumbar Spine Fusion Using Demineralized Bone Matrix (DBM) Mixed With Autograft N/A
Enrolling by invitation NCT05583305 - Prevalence and Etiologies of Intracranial Stenosis in Patients With Antiphospholipid Syndrome
Completed NCT02018445 - Accell Evo3™ Demineralized Bone Matrix in Instrumented Lumbar Spine Fusion N/A
Withdrawn NCT03327272 - Impact of Local Steroid Application in Extreme Lateral Lumbar Interbody Fusion Phase 3
Completed NCT04698512 - MAgicTouch™ Intervention Leap for Dialysis Access (MATILDA) Trial
Active, not recruiting NCT02428582 - Covered Stents Versus Bare-Metal Stents N/A
Completed NCT01742117 - Tailored Antiplatelet Therapy Following PCI Phase 4